LTC Properties stock
LTCNYSELTC Properties, Inc., Real EstateISIN US5021751020
71Score 71 out of 100, Strong
Price and trend
78 / 100
Price history
+23% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 9.8% above it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 5.5% below its 52-week high. Largest decline in 20 years: 53% (September 2016 to March 2020).
Chart figures for advanced users
- SMA 50$43.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$39.88
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$34.04
- The lowest closing price of the last twelve months.
- Resistance$46.33
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- LTC Properties, Inc. belongs to the REIT (Healthcare Facilities) industry (United States) and, with a market value of $2.46B, is number 11 of 18 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $262.85M (up 25.3% year on year) and earnings of $117.97M (up 29.6%).
- MEQIRI Score 71 out of 100 (Strong): rank 13 of 327 in Real Estate, median 55.
Show more
- The P/E is 4.7 (REIT (Healthcare Facilities) median 14.5, own median of recent years 16.4).
- For real estate investment trusts (REITs) what counts is funds from operations (FFO and AFFO). The P/E and the payout ratio of earnings say little here, because depreciation on properties depresses earnings.
- Our model puts fair value at $52.72, with the price 17% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 100% over the last 12 months, REIT (Healthcare Facilities) median 6.6%.Profitability 80
- Modestly valuedP/E 4.7, REIT (Healthcare Facilities) median 14.5, own median 16.4.Valuation 91
- Reliable dividendNo dividend cut for 24 years.
Weaknesses
- Negative free cash flowFree cash flow −$598.24M over the last 12 months.Fundamentals 65
- DilutionShare count up 18% since 2020.Capital allocation 29
Its standout strengths are valuation and profitability, while capital allocation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- calm price action
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $43.93 and expensive above $65.90 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $60.96 (cash-flow model) and $44.48 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $47.61, at 7.8% it would be $60.39.
Valuation metrics
Half from the cash-flow model, half from FFO per share times the median price to FFO of the REIT industry (16.9). For REITs, depreciation on buildings depresses earnings, so FFO counts instead of earnings, here following the industry rule (Nareit) from the filings with the SEC: gains on property sales are deducted where the company reports them in the standard items. The cash-flow model uses AFFO: operating cash flow less maintenance, estimated at 4% of revenue, and less preferred dividends. New construction and acquisitions do not count as running costs there.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 70.4% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 75%, operating 48%, net 45%. Last 12 months: net 100%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 3 Nov 2026EPS reported $6.39 (expected $0.53)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.25−2.3%
- Revenue
- $335.23M+0.1%
- Earnings per share
- $1.86−0.5%
- Revenue
- $398.4M+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +2.9%SHOP acquisition guidance raised by 50% to $900 million, dispositions and loan payoffs $465 million above prior guidance, and SHOP NOI guided to $71 million to $80 million.
“This guidance includes an increase in SHOP acquisitions to $900 million at the midpoint, increasing total SHOP NOI between $71 million and $80 million, and decreasing FAD Capex to approximately $4 million due to the timing of acquisitions.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $654,540 in total. One insider sold, $123,563 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at LTC Properties
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
327 rated companies in Real Estate
- This company
- 71
- Sector median
- 55
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in REIT (Healthcare Facilities)
The next larger and next smaller companies by market value
- Healthcare Realty TrustHR $6.68B46
- AedificaAED.BR $6.09B62
- Sabra Health Care REITSBRA $5.49B50
- National Health InvestorsNHI $3.24B61
- Diversified Healthcare TrustDHC $1.78B32
- National Healthcare Properties, Inc. (NHP)NHP $1.14B41
- Medical Properties TrustMPT $1.06B40
- Care Property InvestCPINV.BR $603.96M65
ETFs that hold LTC Properties
Held by 22 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR S&P Global Dividend Aristocrats UCITS ETF (Dist)ZPRG | 1.82% | 0.45% | €1.63B |
| UBS FTSE EPRA Nareit Developed Green UCITS ETF USD disCSYZ | 0.35% | 0.25% | €207.23M |
| iShares US Property Yield UCITS ETFIQQ7 | 0.19% | 0.40% | €554.91M |
Show 5 more
| WisdomTree US High Dividend UCITS ETF AccWTD9 | 0.14% | 0.29% | €182.46M |
| WisdomTree US Equity Income UCITS ETF EUR Hedged AccWTDY | 0.14% | 0.35% | €204.34M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.14% | 0.30% | €2.28B |
| iShares Developed Markets Property Yield UCITS ETFIQQ6 | 0.13% | 0.59% | €812.71M |
| Amundi FTSE EPRA NAREIT Global UCITS ETF Dist10AJ | 0.12% | 0.24% | €603.52M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.